| ABBV |
AbbVie Inc. |
92%
|
Reciprocal relationship from ABBV graph: Reciprocal relationship from XLO graph: Reciprocal relationship from ABBV graph: Reciprocal relationship from XLO graph: Reciprocal relationship from ABBV gra… |
| ABBV |
AbbVie Inc. |
92%
|
upfront and milestone payments under our collaboration and license agreements with AbbVie |
| F-HOFFMANN-LA-ROCHE-LTD |
F-HOFFMANN-LA-ROCHE-LTD |
90%
|
development event payments under our co-funded clinical trial collaboration with F. Hoffmann-La Roche Ltd, or Roche |
| GILEAD |
GILEAD |
90%
|
upfront and milestone payments under our collaboration and license agreements with Gilead |
| AZN |
AstraZeneca PLC |
72%
|
ction with creating an independent sales and marketing organization. Developing a sales and marketing organization requires significant investment and substantial amount of time and attention from ou… |
| AZN |
AstraZeneca PLC |
72%
|
Reciprocal relationship from AZN graph: Reciprocal relationship from XLO graph: Reciprocal relationship from AZN graph: Reciprocal relationship from XLO graph: Reciprocal relationship from AZN graph:… |
| CELG-RI |
CELG-RI |
72%
|
Reciprocal relationship from CELG-RI graph: Reciprocal relationship from XLO graph: voluntary cooperation in other areas. Individual EU member states will continue to be responsible for assessing non… |
| CELG-RI |
CELG-RI |
72%
|
voluntary cooperation in other areas. Individual EU member states will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technology, and making… |
| GILD |
Gilead Sciences, Inc. |
72%
|
Reciprocal relationship from GILD graph: Reciprocal relationship from XLO graph: t and the stock purchase agreement should be combined into a single contract because they were negotiated and entered … |
| GILD |
Gilead Sciences, Inc. |
72%
|
t and the stock purchase agreement should be combined into a single contract because they were negotiated and entered into in contemplation of one another. The Company accounted for the common stock … |
| HOWL |
Werewolf Therapeutics, Inc. |
72%
|
ction with creating an independent sales and marketing organization. Developing a sales and marketing organization requires significant investment and substantial amount of time and attention from ou… |
| HOWL |
Werewolf Therapeutics, Inc. |
72%
|
Reciprocal relationship from HOWL graph: Reciprocal relationship from XLO graph: ction with creating an independent sales and marketing organization. Developing a sales and marketing organization req… |
| JANX |
Janux Therapeutics, Inc. |
72%
|
Reciprocal relationship from JANX graph: Reciprocal relationship from XLO graph: ction with creating an independent sales and marketing organization. Developing a sales and marketing organization req… |
| JANX |
Janux Therapeutics, Inc. |
72%
|
ction with creating an independent sales and marketing organization. Developing a sales and marketing organization requires significant investment and substantial amount of time and attention from ou… |
| JNJ |
Johnson & Johnson |
72%
|
ction with creating an independent sales and marketing organization. Developing a sales and marketing organization requires significant investment and substantial amount of time and attention from ou… |
| JNJ |
Johnson & Johnson |
72%
|
Reciprocal relationship from JNJ graph: Reciprocal relationship from XLO graph: ction with creating an independent sales and marketing organization. Developing a sales and marketing organization requ… |
| PDSB |
PDS Biotechnology Corporation |
72%
|
ction with creating an independent sales and marketing organization. Developing a sales and marketing organization requires significant investment and substantial amount of time and attention from ou… |
| PDSB |
PDS Biotechnology Corporation |
72%
|
Reciprocal relationship from PDSB graph: Reciprocal relationship from XLO graph: Reciprocal relationship from PDSB graph: Reciprocal relationship from XLO graph: Reciprocal relationship from PDSB gra… |
| REGN |
Regeneron Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from REGN graph: Reciprocal relationship from XLO graph: Reciprocal relationship from REGN graph: Reciprocal relationship from XLO graph: ction with creating an independent sa… |
| REGN |
Regeneron Pharmaceuticals, Inc. |
72%
|
ction with creating an independent sales and marketing organization. Developing a sales and marketing organization requires significant investment and substantial amount of time and attention from ou… |
| SNYNF |
Sanofi |
72%
|
al advantages compared to alternative treatments; • the prevalence and severity of any side effects; • the product’s convenience and ease of administration compared to alternative treatments; • the c… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from XLO graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from XLO graph: al advantages compared to alternati… |
| TKPHF |
Takeda Pharmaceutical Company Limited |
72%
|
Reciprocal relationship from TKPHF graph: Reciprocal relationship from XLO graph: ction with creating an independent sales and marketing organization. Developing a sales and marketing organization re… |
| TKPHF |
Takeda Pharmaceutical Company Limited |
72%
|
ction with creating an independent sales and marketing organization. Developing a sales and marketing organization requires significant investment and substantial amount of time and attention from ou… |
| VIR |
Vir Biotechnology, Inc. |
72%
|
ction with creating an independent sales and marketing organization. Developing a sales and marketing organization requires significant investment and substantial amount of time and attention from ou… |
| VIR |
Vir Biotechnology, Inc. |
72%
|
Reciprocal relationship from VIR graph: Reciprocal relationship from XLO graph: ction with creating an independent sales and marketing organization. Developing a sales and marketing organization requ… |
| ABBVIE-GROUP-HOLDINGS-LIMITED |
ABBVIE-GROUP-HOLDINGS-LIMITED |
62%
|
nd clinical development, including masked multi-specifics, and our clinically-validated masking technology has enabled us to establish top-tier strategic partnerships, including with AbbVie Group Hol… |
| BMY |
Bristol-Myers Squibb Company |
62%
|
Reciprocal relationship from BMY graph: Reciprocal relationship from XLO graph: Reciprocal relationship from BMY graph: Reciprocal relationship from XLO graph: cost- effectiveness of the product, in … |
| COMMERCE-BRISTOL-MYERS-SQUIBB-COMPANY |
COMMERCE-BRISTOL-MYERS-SQUIBB-COMPANY |
62%
|
cost- effectiveness of the product, in addition to the costs required to obtain FDA or other comparable marketing approvals. Nonetheless, product candidates may not be considered medically necessary … |
| DELAWARE-GENERAL-CORPORATION |
DELAWARE-GENERAL-CORPORATION |
62%
|
public float, stockholders' equity and other corporate governance standards. If we are unable to comply with applicable Nasdaq listing standards, shares of our common stock would be subject to delist… |
